Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AbbVie Inc. Director's Dealing 2022

May 25, 2022

29755_dirs_2022-05-25_e83bc395-4d38-448c-b0af-505323df663b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2022-05-23

Reporting Person: SEVERINO MICHAEL (Vice Chairman)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-05-23 Common Stock, $0.01 par value M 46320 $114.36 Acquired 198423 Direct
2022-05-23 Common Stock, $0.01 par value M 11742 $93.50 Acquired 210165 Direct
2022-05-23 Common Stock, $0.01 par value M 21739 $105.92 Acquired 231904 Direct
2022-05-23 Common Stock, $0.01 par value S 68196 $150.79 Disposed 163708 Direct
2022-05-23 Common Stock, $0.01 par value S 11605 $151.53 Disposed 152103 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-05-23 Option (Right to Buy) $114.36 M 46320 Disposed 2028-02-14 Common Stock (46320) Direct
2022-05-23 Option (Right to Buy) $93.50 M 11742 Disposed 2030-02-19 Common Stock (11742) Direct
2022-05-23 Option (Right to Buy) $105.92 M 21739 Disposed 2031-02-17 Common Stock (21739) Direct

Footnotes

F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.